Current Research Studies
HEMOGLOBIN MAINTENANCE IN PEDIATRIC ESRD PATIENTS BY FERRIC PYROPHOSPHATE CITRATE (FPC).
Triferic
What is the goal of the study?
PHASE 3 STUDY whose primary objective is to assess the safety of Triferic administration via dialysate and IV in pediatric CKD-5HD patients. The purpose of this study is to find out if study drug, Triferic, is safe and effective in maintaining the hemoglobin (protein carrying oxygen in red cells in the blood) level in children and adolescents from 6 months to less than 18 years of age with chronic kidney disease on hemodialysis. Participation will last about 47 weeks. It is expected that about 2 – 4 subjects will participate at this center in either the control or the study treatment arm.
Who can participate in the study?
Please contact the study team listed below to learn more.